Nanoscope to Present 126-Week Vision Restoration Data for MCO-010 Gene Therapy in Retinitis Pigmentosa
核心洞察
Nanoscope Therapeutics (搜索) will present long-term follow-up data from the REMAIN (搜索) study of MCO-010 optogenetic therapy for retinitis pigmentosa (搜索) at two major ophthalmology meetings in February 2025.
Dr. Allen Ho from Wills Eye Hospital (搜索) will discuss 126-week efficacy and safety data at the Bascom Palmer Eye Institute (搜索)'s Angiogenesis Meeting, focusing on vision restoration outcomes in advanced RP patients.
The company plans to initiate BLA submission for MCO-010 in Q1 2025 following positive Phase 2b RESTORE (搜索) trial results, while also advancing trials for Stargardt disease (搜索) treatment.
Nanoscope Therapeutics (搜索) is set to present crucial long-term data on its pioneering optogenetic therapy for vision restoration at two prestigious ophthalmology conferences this February. The presentations will showcase 126-week follow-up results from the REMAIN (搜索) study, evaluating MCO-010 in patients with severe vision loss due to retinitis pigmentosa (搜索).
At the Bascom Palmer Eye Institute (搜索)'s 22nd Annual Angiogenesis Meeting, Dr. Allen Ho, Director of Retina Research at Wills Eye Hospital (搜索) and Nanoscope's Chief Medical Advisor, will present detailed findings from the REMAIN (搜索) long-term follow-up study. The presentation, scheduled for February 8, will focus on patients previously treated in the RESTORE (搜索) randomized controlled trial.
The data will receive additional exposure at The Macula Society (搜索)'s 48th Annual Meeting on February 13, where Dr. Victor Gonzalez from Gulf Coast Eye Institute will discuss the therapy's long-term efficacy and safety profile. Both presentations are positioned within sessions dedicated to inherited retinal dystrophies, highlighting the therapy's significance in this field.
Clinical Development Progress
The presentations come at a pivotal time for Nanoscope Therapeutics (搜索), as the company prepares to initiate a Biologics License Application (BLA) submission for MCO-010 in the first quarter of 2025. This milestone follows successful completion of the Phase 2b RESTORE (搜索) trial, which demonstrated positive outcomes in treating retinitis pigmentosa (搜索).
Expanding Therapeutic Applications
Beyond retinitis pigmentosa (搜索), Nanoscope is advancing its gene therapy platform across multiple retinal diseases. The company has completed the Phase 2 STARLIGHT (搜索) trial investigating MCO-010 in Stargardt disease (搜索) patients and plans to launch a Phase 3 registrational trial in early 2025. The therapy has secured FDA Fast Track and orphan drug designations for both conditions, underscoring its potential impact on these serious vision disorders.
The company's pipeline also includes MCO-020, an IND-ready non-viral laser-delivered treatment for geographic atrophy (搜索), and an AAV-based therapy for Leber Congenital Amaurosis (搜索) currently in IND-enabling studies. These developments reflect Nanoscope's commitment to addressing various forms of retinal degeneration through innovative gene therapy approaches.